THIRD DAY
Friday September 29th
TUMOR MICROENVIRONMENT
8.30-10.30 Session V:
François de KERMENGY/ Maria JOSÉ OLIVEIRA
8.30-9.00: Spatial transcriptomics reveals a substantial heterogeneity in TNBC tumor and stroma compartments with potential clinical implications
Pr Christos Sotiriou, Université Libre de Bruxelles , B
9.00-9.30: Immune contexture of radiation response
Dr Jerome Galon, Cordeliers Research Center, FR
9.30-10.00: Low Dose Radiotherapy: from the lab to the clinic
Dr Fernanda Herrera, Lausanne University Hospital, SW
10.00-10.30: Innovative approaches to trigger radiation induced immunological cell death and overcome checkpoint resistance
Pr Jim Welsh, MD Anderson Cancer Center, USA
10.30-11.00 Coffee break
AI, IMAGING AND RADIOMICS
11.00-12.30 Session VI:
Nathan BENZAZON/ Maria VAKALOPOULOU
11.00-11.30: The role of standard imaging in radio-immunotherapy: focus on radiomics and lymphocyte sparing radiotherapy
Pr Philippe Lambin, Maastricht University, NL
11.30-12.00: Predictive and prognostic role of PET in immunotherapy
Dr Désirée Deandreis, Gustave Roussy, FR
12.00-12.30: Next generation radiotherapy at the era of AI and immunotherapy
Pr Eric Deutsch, Gustave Roussy, FR
12.30-14.00 Lunch break and exhibition
ADAPTIVE IMMUNITY
14.00-16.00 Session VII:
Marine FIDELLE/Carolina ALVES COSTA SILVA
14.00-14.30: Fatty Acid metabolic regulation of anti-tumor immunity against irradiated glioblastoma,
Dr Claire Vanpouille-Box, Weill Cornell Medicine, US
14.30-15.00: Human endogenous retroviruses represent a source of shared tumor epitopes for cancer immunotherapy
Pr Stephane Depil, Centre Leon Berard, FR
15.00-15.30: Targeting IL2 signaling with radiotherapy to trigger systemic immunity
Pr Sana Karam, University of Colorado, USA
15.30-16.00: Impact of radiation on intestinal commensals and cancer immunosurveillance
Pr Laurence Zitvogel, Gustave Roussy, FR
16.00-16.30 Coffee break
INNATE IMMUNITY
16.30-18.00 Session VIII:
Lydia MEZIANI/Claudia FOURNIER
16.30-17.00: Clinical and Immune correlates of response to nivolumab plus chemoradiotherapy for locally-advanced cervical cancer – NiCOL study
Dr Emanuela Romano, Institut Curie, FR
17.00-17.30: The non-homogeneous administration of intratumor ionizing radiation doses synergizes with immune checkpoint and CXCR2 blockade
Dr Michele Mondini, Gustave Roussy, FR
17.30 -18.00: Photon and particle radiation innate immune response
Pr Peter Hüber, German Cancer Research Center, G
19.30-00.00 GALA DINNER
